Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00317434
Recruitment Status : Terminated (Due to unacceptable non-dose limiting toxicities, excessive treatment delays and limited clinical responses.)
First Posted : April 24, 2006
Last Update Posted : December 15, 2009
Information provided by:
University of Alabama at Birmingham